Eisenmenger Syndrome: Recent Advances in Pharmacotherapy

ISSN: 1875-6182 (Online)
ISSN: 1871-5257 (Print)


Volume 12, 3 Issues, 2014


Download PDF Flyer




Cardiovascular & Hematological Agents in Medicinal Chemistry

Formerly: Current Medicinal Chemistry - Cardiovascular & Hematological Agents

Aims & ScopeAbstracted/Indexed in


Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
Debabrata Mukherjee
Department of Internal Medicine Texas Tech University
4800 Alberta Avenue El Paso
Texas, 79905
USA


View Full Editorial Board

Subscribe Purchase Articles Order Reprints


Eisenmenger Syndrome: Recent Advances in Pharmacotherapy

Author(s): Sarmad Said, Mateo Porres-Aguilar, Mateo Porres-Munoz and Debabrata Mukherjee

Affiliation: Department of Internal Medicine, Paul L. Foster School of Medicine, Texas Tech University Health Sciences Center at El Paso, 4800 Alberta Avenue, El Paso, Texas, USA 79905.

Abstract

Over the last decade advanced therapies for the management of pulmonary arterial hypertension have been introduced. These agents have also been effective in reducing pulmonary vascular resistance in patients with Eisenmenger syndrome. Specific guidelines focusing on modern therapies for Eisenmenger syndrome however do not exist to date. More recently, clinical trials in patients with Eisenmenger syndrome demonstrated a significant clinical improvement with favorable safety and tolerability profile. This review aims to summarize newly reported pharmacological agents used in patients with Eisenmenger syndrome.

Keywords: Congenital heart disease, endothelin receptor antagonists, eisenmenger syndrome, phosphodiesterase type-5 inhibitors, prostanoids, pulmonary arterial hypertension.

Download Free Rights and Permissions

Article Details

Volume: 11
Issue Number: 4
First Page: 289
Last Page: 296
Page Count: 8
DOI: 10.2174/1871525712666140321095519
Advertisement

Related Journals




Webmaster Contact: urooj@benthamscience.org Copyright © 2014 Bentham Science